Merck Invests €250 Million in Production Value Chain in China


Merck, a leading science and technology company, today inaugurated its € 170 million Nantong pharmaceutical plant, Merck also announced a further investment of around € 80 million in a Life Science Center.


The Nantong pharmaceutical plant, which is dedicated to producing high-quality pharmaceuticals on China’s Essential Drug List. Life Science Center near the Nantong pharmaceutical plant to manufacture high-purity inorganic salts, cell culture media products as well as ready-to-use media.

The additional investment of € 90 million announced today represents the next phase of Merck’s pharmaceutical production plans for China to meet forecast increased demand for medicines to be produced at the site. These strategic investments further support Merck's expansion in China, which is expected to become the world’s second-largest pharmaceutical market by 2018, and enables the company to support the goals of China’s 13th Five Year Plan by investing in technology and developing local talent.

The Nantong pharmaceutical manufacturing site will focus on the production of Glucophage®, Euthyrox® and Concor®, Merck’s leading brands for the treatment of the major chronic diseases diabetes, thyroid disorders and cardiovascular diseases. With the next investment of € 90 million announced today, the facility is designed to accommodate full production capacity of up to 10 billion tablets a year by 2021.


Name Merck
Location China
Type New Production Plants
Investment Cost €250 Million
AirBridgeCargo - Air frieght solutions for your Pharma ACG - Myanmar Pharma Matcon Efficently handling tablets and powders in IBC's MECO - 90 Years